What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Alzheimer's disease
- Psychiatry
His primary areas of investigation include Alzheimer's disease, Cognition, Dementia, Internal medicine and Disease.
He interconnects Psychiatry, Neuropsychology and Degenerative disease in the investigation of issues within Alzheimer's disease.
His work in the fields of Psychiatry, such as Mild cognitive impairment, Memory disorder and Depression, intersects with other areas such as Poison control.
The study incorporates disciplines such as Solanezumab and Clinical psychology in addition to Cognition.
He combines subjects such as Gastroenterology, Placebo and Pathology with his study of Internal medicine.
His study in Disease is interdisciplinary in nature, drawing from both Clinical trial, Psychometrics, Gerontology and Physostigmine.
His most cited work include:
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (9237 citations)
- Current concepts in mild cognitive impairment. (3686 citations)
- A new rating scale for Alzheimer's disease. (3133 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Disease, Internal medicine, Alzheimer's disease, Dementia and Psychiatry.
His biological study spans a wide range of topics, including Clinical trial, Neuroscience, Cholinergic, Gerontology and Family history.
His Internal medicine study combines topics from a wide range of disciplines, such as Placebo, Endocrinology, Surgery and Oncology.
Postmortem studies is closely connected to Degenerative disease in his research, which is encompassed under the umbrella topic of Alzheimer's disease.
Richard C. Mohs studies Dementia, namely Mild cognitive impairment.
His research ties Clinical psychology and Psychiatry together.
He most often published in these fields:
- Disease (32.58%)
- Internal medicine (28.05%)
- Alzheimer's disease (25.79%)
What were the highlights of his more recent work (between 2012-2021)?
- Disease (32.58%)
- Clinical trial (12.67%)
- Solanezumab (5.88%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Disease, Clinical trial, Solanezumab, Placebo and Internal medicine.
His Solanezumab research incorporates elements of Cognition and Intention-to-treat analysis.
His Cognition research is multidisciplinary, incorporating perspectives in Functional impairment and Dementia, Cognitive decline.
His Dementia study integrates concerns from other disciplines, such as Alzheimer's disease, Gerontology and Activities of daily living.
His Alzheimer's disease research includes elements of Alzheimer s dementia and Asymptomatic.
His work on Phases of clinical research, Hippocampal formation and Cognitive impairment as part of general Internal medicine research is frequently linked to Reduction, thereby connecting diverse disciplines of science.
Between 2012 and 2021, his most popular works were:
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease (1046 citations)
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease (698 citations)
- Drug discovery and development: Role of basic biological research. (100 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Alzheimer's disease
- Psychiatry
Richard C. Mohs mainly focuses on Placebo, Solanezumab, Disease, Clinical trial and Cognition.
As a part of the same scientific study, Richard C. Mohs usually deals with the Placebo, concentrating on Internal medicine and frequently concerns with Pathology.
The concepts of his Disease study are interwoven with issues in Drug development, Drug, Intensive care medicine, Clinical study design and Dosing.
His research in Cognition intersects with topics in Dementia, Cognitive decline, Semagacestat and Activities of daily living.
His research integrates issues of Gerontology, Psychiatry, Cognitive deficit, Clinical psychology and Alzheimer's disease in his study of Cognitive decline.
The Semagacestat study combines topics in areas such as Physical therapy and Randomized controlled trial, Randomization.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
